Novel Drug Authorized for Critically Ill COVID-19 Patients
The FDA has issued an emergency use authorization (EUA) for vilobelimab (Gohibic) to treat critically ill adults with COVID-19. In the EUA for the first-in-class monoclonal anti-human complement factor C5a antibody, the agency specified that the therapy be initiated within 48 hours of invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). It is given at […]